ArticleDermatology research and practice2026
Associated Factors and Dose-Response of Steroid-Induced Diabetes Mellitus in Dermatology Inpatients: A Retrospective Study.
Article in Dermatology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associated Factors and Dose-Response of Steroid-Induced Diabetes Mellitus in Dermatology Inpatients: A Retrospective Study.Dermatology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prevalence and associated factors of steroid-induced diabetes mellitus (SDM) in dermatology inpatients receiving systemic glucocorticoid (GC) therapy, with particular focus on characterizing the dose-response relationship. Study Design: Retrospective observational cohort study. Place and Duration of Study: Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, from August 2019 to October 2024. Methodology: A total of 293 patients treated with GCs were included, with 42 classified as having SDM and 251 as controls based on blood glucose monitoring. Data such as demographics, GC dosage, laboratory indices, and follow-up outcomes were analyzed by SPSS 26.0, R 4.4.1, and logistic regression analysis was applied to explore factors associated with the development of SDM. We modeled the nonlinear dose-response between average daily GC dose (methylprednisolone-equivalent) and SDM using multivariable logistic regression with restricted cubic splines, setting 0.6 mg/kg/day as the reference. All tests were two-sided, Results: Among 293 patients, 42 (14.3%) developed SDM and 17 (5.8%) had impaired glucose regulation. SDM cases were older and had higher BMI, hypertension, family history of diabetes, higher average daily GC dose, and more frequent immunosuppressant use. Multivariate regression identified family history of diabetes (OR: 11.16), immunosuppressant use (OR: 3.48), average daily GC dose (OR: 29.13), and serum uric acid (OR: 1.007) as independent factors associated with SDM. The dose-response between average daily GC dose and SDM was significant (Wald Conclusion: SDM is prevalent among dermatology inpatients receiving GCs. High-risk patients may benefit from closer glucose monitoring and individualized dose adjustment; prospective studies are warranted to confirm these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.